Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants

  1. Lingshu Wang
  2. Tongqing Zhou
  3. Yi Zhang
  4. Eun Sung Yang
  5. Chaim A. Schramm
  6. Wei Shi
  7. Amarendra Pegu
  8. Olamide K. Oloniniyi
  9. Amy R. Henry
  10. Samuel Darko
  11. Sandeep R. Narpala
  12. Christian Hatcher
  13. David R. Martinez
  14. Yaroslav Tsybovsky
  15. Emily Phung
  16. Olubukola M. Abiona
  17. Avan Antia
  18. Evan M. Cale
  19. Lauren A. Chang
  20. Misook Choe
  21. Kizzmekia S. Corbett
  22. Rachel L. Davis
  23. Anthony T. DiPiazza
  24. Ingelise J. Gordon
  25. Sabrina Helmold Hait
  26. Tandile Hermanus
  27. Prudence Kgagudi
  28. Farida Laboune
  29. Kwanyee Leung
  30. Tracy Liu
  31. Rosemarie D. Mason
  32. Alexandra F. Nazzari
  33. Laura Novik
  34. Sarah O’Connell
  35. Sijy O’Dell
  36. Adam S. Olia
  37. Stephen D. Schmidt
  38. Tyler Stephens
  39. Christopher D. Stringham
  40. Chloe Adrienna Talana
  41. I-Ting Teng
  42. Danielle A. Wagner
  43. Alicia T. Widge
  44. Baoshan Zhang
  45. Mario Roederer
  46. Julie E. Ledgerwood
  47. Tracy J. Ruckwardt
  48. Martin R. Gaudinski
  49. Penny L. Moore
  50. Nicole A. Doria-Rose
  51. Ralph S. Baric
  52. Barney S. Graham
  53. Adrian B. McDermott
  54. Daniel C. Douek
  55. Peter D. Kwong
  56. John R. Mascola
  57. Nancy J. Sullivan
  58. John Misasi

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

Our key defense against the COVID-19 pandemic is neutralizing antibodies against the SARS-CoV-2 virus elicited by natural infection or vaccination. Recent emerging viral variants have raised concern because of their potential to escape antibody neutralization. Wang et al . identified four antibodies from early-outbreak convalescent donors that are potent against 23 variants, including variants of concern, and characterized their binding to the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Yuan et al . examined the impact of emerging mutations in the receptor-binding domain of the spike protein on binding to the host receptor ACE2 and to a range of antibodies. These studies may be helpful for developing more broadly effective vaccines and therapeutic antibodies. —VV

Article activity feed

  2. Rapid Reviews Infectious Diseases

    Naveenchandra Suryadevara, Robert Carnahan

    Review of "Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants"

    Reviewers: Naveenchandra Suryadevara, Robert Carnahan (Vanderbilt) | 📗📗📗📗◻️

  3. Version published to 10.1126/science.abh1766
  4. ScreenIT

    SciScore for 10.1101/2021.02.25.432969: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board Statementnot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    To do this, we superposed the antibody-RBD complex structures of CB6 (PDB ID 7C01) (25), REGN10933 (PDB ID 6XDG) (26, 27) and LY-CoV555 (PDB ID 7KMG) (18) with the A23-58.1 structure over the RDB region.
    antibody-RBD
    suggested: None
    Software and Algorithms
    SentencesResources
    Science (80-. ). 370, 950–957 (2020). 33. 5 34. 36. X. Shen, H. Tang, C. McDanal, K. Wagh, W. Fischer, J. Theiler, H. Yoon, D. Li, B. F. Haynes, K. O. Sanders, S. Gnanakaran, N. Hengartner, R. Pajon, G. Smith, F. Dubovsky, G. M. Glenn, B. Korber, D. C. Montefiori, bioRxiv, in press, 20 doi:10.1101/2021.01.27.428516. 37.
    bioRxiv
    suggested: (bioRxiv, RRID:SCR_003933)

    Results from OddPub: Thank you for sharing your data.

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  5. Version published to 10.1101/2021.02.25.432969v2 on bioRxiv
  6. Version published to 10.1101/2021.02.25.432969v1 on bioRxiv